A Mycobacterium leprae-specific phenolic glycolipid antigen was purified from Formalin-fixed liver preserved from an advanced lepromatous leprosy patient. Its chemical and immunological properties were compared with those of phenolic glycolipid-I obtained from M. leprae-infected armadillo liver. Based on the findings that the glycolipids from the two sources have the same thin.layer chromatographic properties, infrared absorption spectrum, sugar composition, and seroreactivity, we conclude that large quantities of the phenolic glycolipid-I antigen are produced in human lepromatous leprosy lesions and that Formalin-fixed lepromatous livers and spleens from the prechemotherapeutic era are suitable sources of the glycolipid.
In 1980, Brennan and Barrow (1) reported that a partially purified lipid fraction from Mycobacterium leprae yielded distinct lines of precipitation with sera from lepromatous leprosy patients and M. leprae-infected armadillos. Based on the findings that the activity was unaffected by mild alkali and that the fraction yielded 6-deoxyhexoses upon hydrolysis, it was suggested that the lipid antigens may be related to the phenolphthiocerol-containing lipids of Mycobacterium strains variously called the A, B, or G mycosides. Hunter and Brennan (5) isolated large quantities of the glycolipids from M. leprae-infected armadillo liver residue that was free of the bacillus. The molecular structures of the glycolipids have been fully elucidated (4-7) and named phenolic glycolipid-I (PGL-I), PGL-II, and PGL-III. They are all phenolic-diacylphthiocerol triglycosides in which the trisaccharide portion is unique to the leprosy bacillus. Since the PGLs are strongly antigenic and highly specific for M. leprae, they have received considerable favor as probes for the serodiagnosis of leprosy (2, 3, 12) , are thought to modulate the selective immunological unresponsiveness characteristic of lepromatous leprosy (9) , and may be implicated in the intracellular persistence of the bacillus (6). Nevertheless, there has been no direct evidence to demonstrate that the PGLs as such are produced in human leprosy lesions.
In this paper, we describe the isolation of PGL-I from Formalin-fixed lepromatous liver and conclude that, as was discovered in experimentally infected armadillos, the glycolipid is produced in large quantitie.s in human lepromatous tissue.
Formalin-fixed liver slices (85 g) from an advanced lepromatous patient who had died of laryngeal leprosy were lyophilized for 4 h to remove Formalin and water. The dried specimen (19.5 g) was homogenized in 800 ml of chloroformmethanol (2:1) in an ultrahigh-speed homogenizer ( losis and 1 case with atypical mycobacterial infection, were negative. Thus, the seropositivity rate with the human product is similar to that recorded with the armadillo-derived glycolipid (3).
PGL-I, PGL-II, and PGL-III are unique antigenic glycolipids synthesized exclusively by M. leprae. PGL-I is the major component. The molecular structure (5) is as follows:
and PGL-III are minor metabolic by-products of PGL-I.
The present study demonstrates that the glycolipids from the human and armadillo sources correspond according to several parameters, viz., thin-layer chromatography mobility, infrared absorption, sugar composition, and seroreactivity, and thus clearly indicates that PGL-I is also synthesized in human lepromatous lesions. Young (11) had reported that lipid extracts from human lepromatous skin biopsies contained a 6-deoxyhexose-containing glycolipid, and suggested that the responsible glycolipid may be PGL-I. The present study shows the veracity of this contention.
This study also indicates that Formalin-fixed human lepromatous liver is a highly suitable source of M. leprae antigens. Since large stocks of heavily infected, Formalinfixed livers and spleens are present in the national leprosy hospitals of Japan and other countries, mostly arising from the prechemotherapeutic era, these should provide an alternative source to infected armadillos for the provision of the specific PGL.
